

AMENDMENTS TO THE CLAIMS

1. – 5. (Cancelled)

6. (Currently Amended) A paste comprising, Bacillus Calmette-Guerin – Cell Wall Skeleton (BCG-CWS) and squalane, wherein the paste comprises 6.6 g to 35.2 g of squalane per about 0.67 g of BCG-CWS and has the following properties:

(1) viscosity of between 0.2 and 0.7 poise at 25° C

(2) comprising an assembly of BCG-CWS particles, wherein the particle diameter is from 0.1µm to 20 µm in the particle size distribution and showing a single peak distribution with D10%: 0.23 +/- 0.05 µm and D90%: 0.60 +/- 0.05 µm

(3) obtained by a process for preparation which comprises the following steps:

(a) mixing the BCG-CWS and squalane in an organic solvent that is ~~hexane or~~ heptane which comprises ~~5 to 20~~ about 10% (v/v) of ethanol; and

(b) a step of removing the organic solvent by distillation to obtain the paste comprising BCG-CWS and squalane.

7. – 13. (Cancelled)

14. (Previously presented) The paste according to claim 6 that is formulated as an oil-in-water emulsion, which comprises 0.66 g of the BCG-CWS, 0.4 wt% to 8wt% of the squalane, 0.01% to 3% of polyethylenexysorbitan fatty acid ester and 1 to 10% of mannitol per 2L of water.

15. – 17. (Cancelled)

18. (Previously presented) The paste according to claim 14, wherein the polyethylenexysorbitan fatty acid ester is TWEEN 80 (polysorbate 80).

19. – 40. (Cancelled)

41. (Original) A pharmaceutical composition comprising the emulsion according to claim 14.
42. (Previously Presented) A pharmaceutical composition comprising the paste according to Claim 6.
43. (Previously presented) The paste according to Claim 6, wherein the paste has a viscosity between 0.43 and 0.55 poise at 25 °C.
44. (Previously Presented) The paste according to Claim 6, wherein the paste has a viscosity of approximately 0.43 poise at 25 °C.
45. (Previously Presented) The paste according to Claim 6, where the paste comprises 8.9 to 17.9 g of squalane per about 0.67 g of BCG-CWS.
46. (Cancelled)
47. (Cancelled)